BCBernard Chevalier

Bernard Chevalier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bernard Chevalier has a total of 294 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    A Machine Learning Model Using Cardiac CT and MRI Data Predicts Cardiovascular Events in Obstructive Coronary Artery Disease

    by Théo Pezel, Solenn Toupin, Valérie Bousson, Kenza Hamzi, Thomas Hovasse, Thierry Lefevre, Bernard Chevalier, Thierry Unterseeh, Francesca Sanguineti, Stéphane Champagne, et al.

    Machine learning using combined coronary CT angiography and stress cardiac MRI data outperformed existing scores in predicting major adverse cardiovascular events in patients with newly diagnosed coronary artery disease.


  • Prognostic Value of Cardiac MRI Late Gadolinium Enhancement Granularity in Participants with Ischemic Cardiomyopathy

    by Alexandre Unger, Jérôme Garot, Solenn Toupin, Suzanne Duhamel, Francesca Sanguineti, Thomas Hovasse, Stéphane Champagne, Thierry Unterseeh, Bernard Chevalier, Mariama Akodad, et al.

    A cardiac MRI model incorporating the ischemic late gadolinium enhancement (LGE) parameters of extent, transmurality, location, and midwall LGE significantly outperformed traditional risk factors in predicting all-cause mortality in participants with ischemic cardiomyopathy.


  • Open Access

    Sex‐based treatment and outcomes for coronary bifurcation stenting: A report from the e‐ULTIMASTER registry

    by Gemina Doolub, Mario Iannaccone, Tanveer Rab, Helen Routledge, Adel Aminian, Bernard Chevalier, David Hildick‐Smith, Lotte Jacobs, Ofer Kobo, Ariel Roguin, et al.

    Background: Percutaneous coronary intervention (PCI) for bifurcation lesions can be technically challenging and is associated with higher risk. There is little data on sex‐based differences in strategy and outcomes in bifurcation PCI.Aims: We sought to assess whether differences exist between women and men in the treatment and outcomes of bifurcation PCI.Methods: We collected data on 4006 patients undergoing bifurcation PCI, from the e‐ULTIMASTER study, a prospective, multicentre study enrolling patients from 2014 to 2018. We divided the bifurcation cohort according to sex, with 1‐year follow‐up of outcomes (target lesion failure [TLF], target vessel failure [TVF], and patient‐oriented composite endpoint [POCE]).Findings: Women were older (69.2 ± 10.9 years vs. 64.4 ± 11.0 years), with a greater burden of cardiovascular comorbidities. For true and non‐true bifurcation lesions, women and men were equally likely to undergo a single stent approach (true: 63.2% vs. 63.6%, p = 0.79, non‐true: 95.4% vs. 94.3%, p = 0.32), with similar rates of final kissing balloon (FKB) (37.2% vs. 35.5%, p = 0.36) and proximal optimization (POT) (34.4% vs. 34.2%, p = 0.93) in cases where two stents were used. Lastly, after propensity score matching, there was no difference between women and men in the incidence of the composite endpoints of TLF (5.5% vs. 5.2%, RR 1.05 [95% CI 0.77−1.44], p = 0.75), TVF (6.2% vs. 6.3%, RR 0.99 [95% CI 0.74−1.32], p = 0.96), and POCE (9.9% vs. 9.5%, RR 1.05 [95% CI 0.83−1.31], p = 0.70).Conclusion: In this contemporary, real‐world study of bifurcation PCI, we report no difference in stent strategy between women and men, with similar outcomes at 1‐year.


  • Open Access

    Phenotypic Clustering of Patients With Newly Diagnosed Coronary Artery Disease Using Cardiovascular Magnetic Resonance and Coronary Computed Tomography Angiography

    by Théo Pezel, Thierry Unterseeh, Thomas Hovasse, Anouk Asselin, Thierry Lefèvre, Bernard Chevalier, Antoinette Neylon, Hakim Benamer, Stéphane Champagne, Francesca Sanguineti, et al.

    Background: Epidemiological characteristics and prognostic profiles of patients with newly diagnosed coronary artery disease (CAD) are heterogeneous. Therefore, providing individualized cardiovascular (CV) risk stratification and tailored prevention is crucial.Objective: Phenotypic unsupervised clustering integrating clinical, coronary computed tomography angiography (CCTA), and cardiac magnetic resonance (CMR) data were used to unveil pathophysiological differences between subgroups of patients with newly diagnosed CAD.Materials and Methods: Between 2008 and 2020, consecutive patients with newly diagnosed obstructive CAD on CCTA and further referred for vasodilator stress CMR were followed for the occurrence of major adverse cardiovascular events (MACE), defined by cardiovascular death or non-fatal myocardial infarction. For this exploratory work, a cluster analysis was performed on clinical, CCTA, and CMR variables, and associations between phenogroups and outcomes were assessed.Results: Among 2,210 patients who underwent both CCTA and CMR, 2,015 (46% men, mean 70 ± 12 years) completed follow-up [median 6.8 (IQR 5.9–9.2) years], in which 277 experienced a MACE (13.7%). Three mutually exclusive and clinically distinct phenogroups (PG) were identified based upon unsupervised hierarchical clustering of principal components: (PG1) CAD in elderly patients with few traditional risk factors; (PG2) women with metabolic syndrome, calcified plaques on CCTA, and preserved left ventricular ejection fraction (LVEF); (PG3) younger men smokers with proximal non-calcified plaques on CCTA, myocardial scar, and reduced LVEF. Using survival analysis, the occurrence of MACE, cardiovascular mortality, and all-cause mortality (all p < 0.001) differed among the three PG, in which PG3 had the worse prognosis. In each PG, inducible ischemia was associated with MACE [PG1, Hazards Ratio (HR) = 3.09, 95% CI, 1.70–5.62; PG2, HR = 3.62, 95% CI, 2.31–5.7; PG3, HR = 3.55, 95% CI, 2.3–5.49; all p < 0.001]. The study presented some key limitations that may impact generalizability.Conclusions: Cluster analysis of clinical, CCTA, and CMR variables identified three phenogroups of patients with newly diagnosed CAD that were associated with distinct clinical and prognostic profiles. Inducible ischemia assessed by stress CMR remained associated with the occurrence of MACE within each phenogroup. Whether automated unsupervised phenogrouping of CAD patients may improve clinical decision-making should be further explored in prospective studies.


  • Open Access

    Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial

    by Pieter C. Smits, Enrico Frigoli, Jan Tijssen, Peter Jüni, Pascal Vranckx, Yukio Ozaki, Marie-Claude Morice, Bernard Chevalier, Yoshinobu Onuma, Stephan Windecker, et al.

    Background: The optimal duration of antiplatelet therapy (APT) in patients at high bleeding risk with or without oral anticoagulation (OAC) after coronary stenting remains unclear. Methods: In the investigator-initiated, randomize, open-label MASTER DAPT trial (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen), 4579 patients at high bleeding risk were randomized after 1-month dual APT to abbreviated or nonabbreviated APT strategies. Randomization was stratified by concomitant OAC indication. In this subgroup analysis, we report outcomes of populations with or without an OAC indication. In the population with an OAC indication, patients changed immediately to single APT for 5 months (abbreviated regimen) or continued ≥2 months of dual APT and single APT thereafter (nonabbreviated regimen). Patients without an OAC indication changed to single APT for 11 months (abbreviated regimen) or continued ≥5 months of dual APT and single APT thereafter (nonabbreviated regimen). Coprimary outcomes at 335 days after randomization were net adverse clinical outcomes (composite of all-cause death, myocardial infarction, stroke, and Bleeding Academic Research Consortium 3 or 5 bleeding events); major adverse cardiac and cerebral events (all-cause death, myocardial infarction, and stroke); and type 2, 3, or 5 Bleeding Academic Research Consortium bleeding. Results: Net adverse clinical outcomes or major adverse cardiac and cerebral events did not differ with abbreviated versus nonabbreviated APT regimens in patients with OAC indication (n=1666; hazard ratio [HR], 0.83 [95% CI, 0.60–1.15]; and HR, 0.88 [95% CI, 0.60–1.30], respectively) or without OAC indication (n=2913; HR, 1.01 [95% CI, 0.77–1.33]; or HR, 1.06 [95% CI, 0.79–1.44]; P interaction =0.35 and 0.45, respectively). Bleeding Academic Research Consortium 2, 3, or 5 bleeding did not significantly differ in patients with OAC indication (HR, 0.83 [95% CI, 0.62–1.12]) but was lower with abbreviated APT in patients without OAC indication (HR, 0.55 [95% CI, 0.41–0.74]; P interaction =0.057). The difference in bleeding in patients without OAC indication was driven mainly by a reduction in Bleeding Academic Research Consortium 2 bleedings (HR, 0.48 [95% CI, 0.33–0.69]; P interaction =0.021). Conclusions: Rates of net adverse clinical outcomes and major adverse cardiac and cerebral events did not differ with abbreviated APT in patients with high bleeding risk with or without an OAC indication and resulted in lower bleeding rates in patients without an OAC indication. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03023020.


  • Multiple Distal Saccular Coronary Aneurysms Associated With Pheochromocytoma

    by Samuel Larue-Grondin, Bernard Chevalier, Fabrice Ieroncig, Benoit Tremblay

  • Imaging and 2‐year clinical outcomes of thin strut sirolimus‐eluting bioresorbable vascular scaffold: The MeRes‐1 extend trial

    by Alexandre Abizaid, Sasko Kedev, Rosli Bin Mohd Ali, Teguh Santoso, Angel Cequier, Robert‐Jan Van Geuns van Geuns, Bernard Chevalier, Farrel Hellig, Ricardo Costa, Yoshinobu Onuma, et al.

    Objectives: This study explores the safety and efficacy of thin strut MeRes100 sirolimus‐eluting bioresorbable vascular scaffold (BRS) in patients with de novo coronary artery lesions.Background: In interventional cardiology, the emergence of BRS technology is catalyzing the next paradigm shift.Methods: The MeRes‐1 Extend was a multicenter, prospective, single‐arm, open‐label study enrolling 64 patients in Spain, Macedonia, Brazil, South Africa, Malaysia, and Indonesia. The safety endpoint was major adverse cardiac events (MACE) which composed of cardiac death, myocardial infarction (MI), and ischemia‐driven target lesion revascularization (ID‐TLR). The imaging efficacy endpoint was mean in‐scaffold late lumen loss (LLL) evaluated by quantitative coronary angiography (QCA). Optical coherence tomography (OCT) imaging was performed at baseline and 6‐month follow‐up.Results: A total of 69 target lesions were identified in 64 enrolled patients (mean age 58.30 ± 9.02 years). Of the treated lesions, 49 (71.01%) lesions were of type B2/C. Procedural and device success was achieved in 64 and 62 patients, respectively. At 2‐year follow‐up, MACE was reported in one patient (1.61%) in the form of ID‐TLR. There was no case of MI, cardiac death or scaffold thrombosis through 2‐year. In a subset of 32 patients, paired QCA showed mean in‐scaffold LLL of 0.18 ± 0.31 mm at 6‐month follow‐up. In a subset of 21 patients, OCT revealed 97.95 ± 3.69% strut coverage with mean scaffold area of 7.56 ± 1.79 mm2 and no evidence of strut malapposition.Conclusions: The clinical and imaging outcomes of MeRes‐1 Extend trial demonstrated favorable safety and efficacy of MeRes100 sirolimus‐eluting BRS in patients with de novo coronary artery lesions.


  • Hemodynamic Performances and Clinical Outcomes in Patients Undergoing Valve-in-Valve Versus Native Transcatheter Aortic Valve Implantation

    by Mariama Akodad, Alexandra Meilhac, Thierry Lefèvre, Guillaume Cayla, Benoit Lattuca, Cécile Autissier, Claire Duflos, Thomas Gandet, Jean-Christophe Macia, Delphine Delseny, et al.


  • Open Access

    Comparison of long‐term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimus‐eluting stent or permanent polymer everolimus‐eluting stent: 5‐year results of the CENTURY II randomized clinical trial

    by Andrés Iñiguez, Bernard Chevalier, Gert Richardt, Antoinette Neylon, Victor A. Jiménez, Ran Kornowski, Didier Carrie, Raul Moreno, Emanuele Barbato, Antoni Serra‐Peñaranda, et al.

    Objectives: To assess the long‐term safety and efficacy of a sirolimus‐eluting stent with bioresorbable polymer (BP‐SES; Ultimaster), in comparison to a benchmark everolimus‐eluting, permanent polymer stent (PP‐EES; Xience), in a prespecified subgroup of patients with multivessel coronary artery disease (MVD) enrolled in the CENTURY II trial.Background: The use of coronary stenting in high‐risk subgroups, like MVD patients, is rising. The clinical evidence, including long‐term comparative analysis of the efficacy and safety benefits of different new‐generation drug eluting stents, however, remains insufficient.Methods: Among 1,119 patients (intention‐to‐treat) enrolled in the CENTURY II prospective, randomized, single‐blind, multicenter trial, a prespecified subgroup of 456 MVD patients were allocated by stratified randomization to treatment with BP‐SES (n = 225) or PP‐EES (n = 231). The previously reported primary endpoint of this study was freedom from target lesion failure (TLF: a composite of cardiac death, target vessel‐related myocardial infarction [MI] and clinically‐indicated target lesion revascularization) at 9 months.Results: In this MVD substudy, baseline patient, lesion and procedure characteristics were similar between the treatment arms. At 1 and 5 years, both BP‐SES and PP‐EES displayed low and comparable rates of TLF (5.3 vs. 7.8%; p = .29 and 10.2 vs. 13.4%; p = .29), and definite or probable stent thrombosis (0.4 vs. 1.3%; p = .33 and 0.9 vs. 1.7%; p = .43), respectively. Composite endpoint of cardiac death and MI, and patient‐oriented composite endpoint of any death, MI, and coronary revascularizations were also similar.Conclusions: These results confirm good long‐term safety and efficacy of the studied bioresorbable polymer stent in this high‐risk patient population.


  • Implementation of the transradial approach as an alternative vascular access for transcatheter aortic valve replacement guidance: Experience from a high‐volume center

    by Leticia Fernandez‐Lopez, Bernard Chevalier, Thierry Lefèvre, Marco Spaziano, Thierry Unterseeh, Stéphane Champagne, Hakim Benamer, Francesca Sanguineti, Philippe Garot, Thomas Hovasse

    Objective: This study sought to assess the potential benefits of the transradial approach (TRA) as an alternative vascular access to the classical contralateral femoral approach for transcatheter aortic valve replacement (TAVR).Background: Vascular and bleeding complications in TAVR have gradually decreased owing to operator experience and downsizing of the delivery system. However, about 1/4 of vascular access site complications are related to the transfemoral (TF) secondary access.Methods: We compared the outcomes at 30 days according to VARC‐2 after TAVR of a prospective cohort of 217 consecutive patients undergoing right or left TRA as the second vascular access (TRA‐TF TAVR) and a retrospective cohort of 194 consecutive patients undergoing TF approach as a second vascular access (TF‐TF TAVR).Results: Baseline clinical characteristics and risk scores were well matched in both groups. Procedural success rate was 99.7%. Fluoro time was significantly lower in the TF‐TF TAVR group (16.9 ± 7.2 vs. 19.1 ± 7.8 min, P = 0.003); however, there was no significant difference in x‐ray exposure, procedure time or amount of contrast used. In the TRA‐TF TAVR group, there were no complications related to the TRA access and there were less vascular and bleeding complications (18.0% vs. 9.7%, P = 0.014; 17.0% vs. 9.2%, P = 0.026, respectively), although blood transfusion requirement or hospitalization duration stay were similar in both groups.Conclusions: TRA approach as alternative secondary vascular access in TAVR is safe and feasible and is associated with a significant decrease in vascular and bleeding complications. Further, large‐scale studies are warranted to confirm the potential benefit of this approach.